Status:
COMPLETED
Effect of Rosiglitazone
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Healthy
Eligibility:
MALE
18-35 years
Phase:
NA
Brief Summary
To evaluate : * acute effects of a single dose of 8 mg rosiglitazone (therapeutic dose) * on insulin secretion and * insulin sensitivity in 12 healthy male subjects.
Eligibility Criteria
Inclusion
- BMI between 18.0 and 24.0
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
November 1 2004
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00285142
Start Date
June 1 2004
End Date
November 1 2004
Last Update
June 10 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre d'Investigation Clinique
Montpellier, France, 34295, cedex 5